Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human endostatin plus concurrent chemoradiotherapy for esophageal squamous cell carcinoma
ChiCTR-TRC-13003908Phase 2Completed
- Sponsor
- Sichuan Cancer Hospital & Institute
- Start
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of endostar in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Sichuan Cancer Hospital & Institute. Primary endpoints: Serum VEGF, CT perfusion parameters and 6 more. Started Dec 2013; status: completed.
02
Drugs
endostar
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR-TRC-13003908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003908.